Jordan Sloshower
Clinical Instructor of Psychiatry at Yale School of Medicine
Data updated
Research Footprint
Jordan Sloshower appears in 5 tracked papers (2018–2024), most studied alongside Psilocybin, LSD and DMT, across Equity and Ethics, Substance Use Disorders (SUD) and Anxiety Disorders.
Most-cited paper: Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial (148 citations).
Frequent co-authors: Deepak Cyril D’Souza, Brian Pittman and Emmanuelle Schindler.
Background & Research
Jordan Sloshower, MD, MSc is a board-certified psychiatrist, researcher, and educator focused on therapeutic applications of psychedelic medicines and their integration with psychotherapy and other healing modalities. He is a faculty member in the Yale Department of Psychiatry and has served as an investigator and therapist in psilocybin-assisted therapy trials. His work also reflects interests in medical anthropology, global health, and ethical stewardship of psychedelic practice.
Key Impact
He is a Yale psychiatrist and psychedelic therapy researcher known for clinical and conceptual work on psilocybin-assisted therapy, including depression treatment trials and psychedelic medicine integration.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Jordan Sloshower is associated with.
VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →